Unrelated Bone Marrow Transplantation with a Reduced Toxicity Myeloablative Conditioning Regimen in Wiskott-Aldrich Syndrome
Open Access
- 1 January 2008
- journal article
- case report
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 23 (1) , 146-148
- https://doi.org/10.3346/jkms.2008.23.1.146
Abstract
Kang HJ, et al. J Korean Med Sci. 2008 Feb;23(1):146-148. http://dx.doi.org/10.3346/jkms.2008.23.1.146This publication has 7 references indexed in Scilit:
- Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemiaBone Marrow Transplantation, 2004
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSBlood, 2004
- Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsBlood, 2003
- Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomesTransplantation and Cellular Therapy, 2002
- Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndromeBritish Journal of Haematology, 2002
- Treatment of Chronic Granulomatous Disease with Nonmyeloablative Conditioning and a T-Cell–Depleted Hematopoietic AllograftNew England Journal of Medicine, 2001
- Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.Blood, 2001